New drug FORX-428 targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …
Phase: PHASE1 • Sponsor: FoRx Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC